OSE Immunotherapeutics - One step closer to key data readouts
OSE Immunotherapeutics has announced the completion of patient enrolment in its Phase II CoTikiS trial, marking another step in the clinical...
202 Views
OSE Immunotherapeutics - Confidence boost with AbbVie partnership
OSE Immunotherapeutics has announced a global licence and collaboration agreement with AbbVie to develop OSE-230, a novel monoclonal antibody, for...
208 Views
OSE Immunotherapeutics - Encouraging OSE-279 clinical update
At the 2024 ESMO Targeted Anticancer Therapies Congress, OSE Immunotherapeutics (OSE) presented encouraging interim results from the Phase I/II...
205 Views
OSE Immunotherapeutics - Active year ahead for proprietary programmes
OSE has refreshed its outlook for 2024, including the commencement of the confirmatory Phase III trial for lead asset Tedopi (an off-the-shelf,...
216 Views
OSE Immunotherapeutics - Timely FR104/VEL-101 update with Phase II plans
OSE Immunotherapeutics (OSE) has shared a positive update on the FIRsT clinical trial assessing FR104/VEL-101 (an anti-CD28 monoclonal antibody) as...
259 Views